The Centers for Disease Control and Prevention (CDC) has recently updated its vaccine recommendations for three critical diseases: meningococcal, respiratory syncytial virus (RSV), and chikungunya.

The updated recommendations are pending final approval by the director of the CDC and the Department of Health and Human Services.

Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that during its regular meeting on April 16, the U.S. Centers for Disease Control and Prevention’s (CDC) ...

The Advisory Committee on Immunization Practices voted Wednesday to recommend lowering the age at which adults can get a ...

A panel of federal health experts on Wednesday recommended expanded vaccine options for several diseases, including ...

The CDC's Advisory Committee on Immunization Practices (ACIP) unanimously recommended that U.S. travelers ages 12 years and ...

The U.S. Centers for Disease Control's vaccine advisory committee voted to recommend the single-dose vaccine, Vimkunya, for the prevention chikungunya in 12 years and older traveling to a country ...

A key group of government advisers voted to expand the use of vaccines for a common respiratory illness, providing a boost to ...

For meningococcal vaccines, ACIP recommended that GSK's pentavalent vaccine (Penmenvy), designed to protect against A, B, C, ...

VIMKUNYA was approved by the U.S. Food and Drug Administration (FDA) and the European Commission in February 2025 6,7. Bavarian Nordic has also filed for approval of the vaccine in the United Kingdom ...

The inoculation, produced by the Butantan Institute in partnership with Austrian Valneva, had its registration approved this ...

In the evening of April 22, Valneva will attend the Vaccine Industry Excellence Awards ceremony, where it is a finalist for the Best Biotech Award and Best Prophylactic Vaccine Award for VLA15, the ...